摘要
轻度认知障碍(MCI)是一种具有较高风险的患痴呆症的相关的疾病类型。以前的证据表明,有MCI的个体频发痴呆症的行为和精神的症状(BPSDs)。这些神经精神的临床表现可预示着痴呆的转化。然而,为探讨一般人群样本有MCI的个体里BPSDs的发病率这一方面,没有更新的的系统的论述。我们对于临床的MCI受试者患任何或特定的BPSDs发病率进行了系统的回顾,与认知完好和/或有痴呆的受试者比较,以总结研究结果。检索了1990年1月1日到2015年1月3日间的PubMed / MEDLINE,EMBASE,和PsycINFO数据库中评估普通人群里有MCI个体的BPSDs患病率的研究。21项研究符合纳入标准。用New Castle-Ottawa Scale(NOS)文献质量评价表修改后的版本来评估横向研究,研究的整体方法学质量有变化。在研究里更频发的BPSDs有抑郁(平均患病率:29.8%;范围:6.8-63.3 %),睡眠障碍(平均患病率:18.3%;范围:7.9-49.0 %),冷漠(平均患病率:15.2%;范围:2.3-18.5 %)。任何BPSDs患病率的范围为12.8-66.0 %。根据MCI亚型的出现,在BPSDs患病率差异上没有一致的模式。研究里考虑到MCI的不同诊断标准和使用不同的工具来评估在这一人群中的BPSDs。总之,社区居住人群里有MCI的普遍存在BPSDs。然而,对BPSDs人群有待建立一致的社会人口学和临床的相互关系。
关键词: 阿尔茨海默病、抑郁症、痴呆、轻度认知障碍、神经精神症状、患病率。
Current Alzheimer Research
Title:Neuropsychiatric Disturbances in Mild Cognitive Impairment (MCI): A Systematic Review of Population-Based Studies
Volume: 13 Issue: 10
Author(s): Cristiano A. Köhler, Thaís F. Magalhaes, Joao M.M.P. Oliveira, Gilberto S. Alves, Christian Knochel, Viola Oertel-Knöchel and Johannes Pantel, André F. Carvalho
Affiliation:
关键词: 阿尔茨海默病、抑郁症、痴呆、轻度认知障碍、神经精神症状、患病率。
摘要: Mild cognitive impairment (MCI) is a nosological entity associated with a higher risk of developing dementia. Previous evidence indicates that behavioral and psychological symptoms of dementia (BPSDs) frequently occur in individuals of MCI. These neuropsychiatric manifestations may predict conversion to dementia. However, no updated systematic review has been conducted aiming to investigate the prevalence of BPSDs in MCI in general population samples. We conducted a systematic review to summarize research results regarding the prevalence of any or specific BPSDs in MCI subjects out of the clinical setting, compared to subjects who are either cognitively intact and/or demented. The PubMed/MEDLINE, EMBASE, and PsycInfo databases were searched from January 1st, 1990 to January 3rd, 2015 for general population studies in which the prevalence of BPSDs in individuals with MCI was estimated. Twenty-one studies met inclusion criteria. Studies varied in overall methodological quality as evaluated with a modified version of the New Castle-Ottawa Scale for cross-sectional studies. Depression (median prevalence: 29.8%; range: 6.8-63.3%), sleep disturbances (median prevalence: 18.3%; range: 7.9-49.0%), and apathy (median prevalence: 15.2%; range: 2.3-18.5%) were the more frequent BPSDs across studies. The prevalence range for any BPSD was 12.8-66.0%. No consistent pattern for differences in the prevalence of BPSDs according to MCI subtype emerged. Studies considered different diagnostic criteria for MCI and used different instruments to assess BPSDs in this population. In conclusion, BPSDs are prevalent among communitydwelling individuals with MCI. However, consistent socio-demographic and clinical correlates for BPSDs in this population remains to be established.
Export Options
About this article
Cite this article as:
Cristiano A. Köhler, Thaís F. Magalhaes, Joao M.M.P. Oliveira, Gilberto S. Alves, Christian Knochel, Viola Oertel-Knöchel and Johannes Pantel, André F. Carvalho , Neuropsychiatric Disturbances in Mild Cognitive Impairment (MCI): A Systematic Review of Population-Based Studies, Current Alzheimer Research 2016; 13 (10) . https://dx.doi.org/10.2174/1567205013666160502123129
DOI https://dx.doi.org/10.2174/1567205013666160502123129 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science Non-Globular Structures of Tandem Repeats in Proteins
Protein & Peptide Letters A Second Look into the Oxidant Mechanisms in Alzheimers Disease
Current Neurovascular Research Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimers Disease
Current Alzheimer Research The Peripheral Nervous System and the Pathogenesis of Prion Diseases
Current Molecular Medicine Endoplasmic Reticulum Dysfunction in Brain Pathology: Critical Role of Protein Synthesis
Current Neurovascular Research Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
Current Neuropharmacology Postoperative Delirium
Current Drug Targets Low Levels of High Density Lipoprotein Increase the Severity of Cerebral White Matter Changes:Implications for Prevention and Treatment of Cerebrovascular Diseases
Current Alzheimer Research Natural Non-Trasgenic Animal Models for Research in Alzheimers Disease
Current Alzheimer Research Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine
Current Pharmaceutical Design Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design Identification and Temporal Characterization of Features Associated with the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Impact of the CD40-CD40L Dyad in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Allopregnanolone Increases the Number of Dopaminergic Neurons in Substantia Nigra of a Triple Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Histamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases
Current Topics in Medicinal Chemistry Hypothermia and Alzheimer's Disease Neuropathogenic Pathways
Current Alzheimer Research Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design Cofilin/Actin Rod Formation by Dysregulation of Cofilin-1 Activity as a Central Initial Step in Neurodegeneration
Mini-Reviews in Medicinal Chemistry